Browsing by Author "Alhazzani, Waleed"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section
    (Elsevier, 2021-10) Alhazzani, Waleed; Alshahrani, Mohammed; Alshamsi, Fayez; Aljuhani, Ohoud; Eljaaly, Khalid; Hashim, Samaher; Alqahtani, Rakan; Alsaleh, Doaa; Al Duhailib, Zainab; Algethamy, Haifa; Al-Musawi, Tariq; Alshammari, Thamir; Alqarni, Abdullah; Khoujah, Danya; Tashkandi, Wail; Dahhan, Talal; Almutairi, Najla; Alserehi, Haleema A.; Al-Yahya, Maytha; Al-Judaibi, Bandar; Arabi, Yaseen M.; Abualenain, Jameel; Alotaibi, Jawaher M.; Al Bshabshe, Ali; Alharbi, Reham; Al-Hameed, Fahad; Elhazmi, Alyaa; Almaghrabi, Reem S.; Almaghlouth, Fatma; Abedalthagafi, Malak; Al Khathlan, Noor; Al-Suwaidan, Faisal A.; Bunyan, Reem F.; Baw, Bandar; Alghamdi, Ghassan; Al Hazmi, Manal; Mandourah, Yasser; Assiri, Abdullah; Enani, Mushira; Alawi, Maha; Aljindan, Reem; Aljabbary, Ahmed; Alrbiaan, Abdullah; Algurashi, Fahd; Alsaawi, Abdulmohsen; Alenazi, Thamer H.; Alsultan, Mohammed A.; Alqahtani, Saleh A.; Memish, Ziad; Al-Tawfiq, Jaffar A.; Al-Jedai, Ahmed; Medicine, School of Medicine
    BACKGROUND: The rapid increase in coronavirus disease 2019 (COVID-19) cases during the subsequent waves in Saudi Arabia and other countries prompted the Saudi Critical Care Society (SCCS) to put together a panel of experts to issue evidence-based recommendations for the management of COVID-19 in the intensive care unit (ICU). METHODS: The SCCS COVID-19 panel included 51 experts with expertise in critical care, respirology, infectious disease, epidemiology, emergency medicine, clinical pharmacy, nursing, respiratory therapy, methodology, and health policy. All members completed an electronic conflict of interest disclosure form. The panel addressed 9 questions that are related to the therapy of COVID-19 in the ICU. We identified relevant systematic reviews and clinical trials, then used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach as well as the evidence-to-decision framework (EtD) to assess the quality of evidence and generate recommendations. RESULTS: The SCCS COVID-19 panel issued 12 recommendations on pharmacotherapeutic interventions (immunomodulators, antiviral agents, and anticoagulants) for severe and critical COVID-19, of which 3 were strong recommendations and 9 were weak recommendations. CONCLUSION: The SCCS COVID-19 panel used the GRADE approach to formulate recommendations on therapy for COVID-19 in the ICU. The EtD framework allows adaptation of these recommendations in different contexts. The SCCS guideline committee will update recommendations as new evidence becomes available.
  • Thumbnail Image
    Item
    Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation
    (Wolters Kluwer, 2021-07) Alqahtani, Saleh A.; Barry, Mazin; Memish, Ziad; Hashim, Almoutaz; Alfares, Mona A.; Alghamdi, Saad A.; Al-Hamoudi, Waleed K.; Al-Judaibi, Bandar; Alhazzani, Waleed; Al-Tawfiq, Jaffar A.; Abaalkhail, Faisal; Medicine, School of Medicine
    Patients with chronic liver disease (CLD) and liver transplant recipients are at increased risk of morbidity and mortality from coronavirus disease 2019 (COVID-19). Although several studies demonstrated the safety and efficacy of COVID-19 vaccines in the general population, data in CLD patients and liver transplant recipients are lacking. Two COVID-19 vaccines were approved by the Saudi Food and Drug Authority and rolled out to several million recipients in Saudi Arabia. These vaccines are mRNA-based vaccine BNT162b2 from Pfizer/BioNTech and adenovirus-based AZD1222 from Oxford/AstraZeneca from three manufacturing sites (EU Nodes, Serum Institute of India, and South Korea Bio). The Saudi Association for the Study of Liver diseases and Transplantation (SASLT) has reviewed the available evidence and issued interim recommendations for COVID-19 vaccination in CLD and liver transplant recipients. Since there is no evidence contradicting the safety and immunogenicity of the currently approved COVID-19 vaccines in patients with CLD and hepatobiliary cancer and liver transplant recipients, the SASLT recommends vaccination in those patient populations. CLD and hepatobiliary cancer patients and liver transplant recipients should be prioritized depending on the risk factors for severe COVID-19. In transplant recipients, the optimal timing of vaccination remains unknown; however, immunization is recommended after the initial immunosuppression phase. Patients with CLD and liver transplant candidates or recipients should be closely monitored after COVID-19 vaccination. These patient populations should be included in future clinical trials to provide further evidence on the efficacy and safety of COVID-19 vaccines.